Edison issues review on Worldwide Healthcare Trust

RNS Number : 7475T
Worldwide Healthcare Trust PLC
26 July 2022
 

London, UK, 26 July 2022

 

Edison issues review on Worldwide Healthcare Trust (WWH)

Worldwide Healthcare Trust (WWH) has two co-managers, Sven Borho and Trevor Polischuk at global healthcare specialist OrbiMed. Borho recently presented at the WWH AGM and despite disappointing performance in FY22 (March year-end), which he notes was a 'mirror image' of FY21, the manager remains optimistic about the trust's prospects. He is hopeful that May/June 2022 marked the low point in the absolute and relative performance of biotech stocks and is confident that the focus on favouring emerging biotech and emerging market stocks over large-cap pharma companies will once again be the correct strategy for WWH's shareholders. Borho considers that the trust's portfolio offers investors a 'mix of the big guys', which gives some stability, along with 'explosive growth' companies, and this approach has delivered significant outperformance versus WWH's benchmark over the long term.

 

WWH's shares are trading at a 6.9% discount to its cum-income NAV, which is wider than the 0.3% to 3.3% range of average discounts over the last one, three, five and 10 years. This may be due to a period of meaningful underperformance versus the trust's benchmark in FY22. WWH's board employs a discount-control mechanism, aiming to ensure a maximum 6% share price discount to ex-income NAV in normal market conditions. 


Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: E dison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority .

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Mel Jenner +44 (0)20 3077 5700 investmenttrusts@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn  www.linkedin.com/company/edison-group-/

Twitter    www.twitter.com/Edison_Inv_Res

YouTube  www.youtube.com/edisonitv

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRARFMRTMTITMPT
UK 100

Latest directors dealings